表紙
市場調查報告書

流感疫苗的全球市場的預測:2020年∼2028年

Global Influenza Vaccine Market Forecast 2020-2028

出版商 Inkwood Research 商品編碼 931050
出版日期 內容資訊 英文 172 Pages
商品交期: 2-3個工作天內
價格
流感疫苗的全球市場的預測:2020年∼2028年 Global Influenza Vaccine Market Forecast 2020-2028
出版日期: 2020年04月03日內容資訊: 英文 172 Pages
簡介

流感,是由流感病毒引起的急性呼吸疾病,由於病毒不斷變化,每年需要開發新的疫苗,不過,一般認為為疫苗的開發,從2億美元達到5億美元的高額的費用需要從15年到20年的期間。現在市場上為少數的有力企業競爭互相的情形,由於技術的進步和各國政府推動疫苗接種計劃等要素所促進,在2020年到2028年間預測將以6.43%的年複合成長率持續成長。

本報告提供全球流感疫苗市場調查,市場力學,產業趨勢,各類型、各技術、各年齡層、各傳送模式、各地區的分析,企業簡介等資訊。

目錄

第1章 調查範圍和調查方法

  • 調查目的
  • 調查範圍
  • 調查方法
  • 前提條件與規定

第2章 摘要整理

  • 估計市場規模
  • 市場概要

第3章 市場力學

  • 市場分析
  • 市場定義
  • 主要的促進成長因素
    • 為了根絕來自社會的疾病各國政府推動的疫苗接種計劃
    • 流感病例的增加
    • 技術的進步
  • 主要的規定
    • 高額的開發成本
    • 長期的開發過程

第4章 主要分析結果

  • 投資相關主要考察
  • 波特的五力分析
    • 買主談判力
    • 供應商談判力
    • 替代品的威脅
    • 新加入廠商勢力的威脅
    • 產業內的競爭
  • 市場機會矩陣
  • 供應商的勢力圖

第5章 各類型的市場分析

  • 四價疫苗
  • 三價疫苗

第6章 各技術的市場分析

  • 雞蛋為基礎的技術
  • 細胞為基礎的技術

第7章 各年齡層的市場分析

  • 兒童年齡層
  • 成人年齡層

第8章 各傳送模式的市場分析

  • 注射
  • 鼻腔用噴霧

第9章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 俄羅斯
    • 比利時
    • 波蘭
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲,紐西蘭
    • 泰國
    • 印尼
    • 越南
    • 其他
  • 其他
    • 南美
    • 中東、非洲

第10章 企業簡介

  • MERCK
  • NOVARTIS AG
  • PFIZER, INC
  • SANOFI
  • BIODIEM
  • EMERGENT BIOSOLUTIONS
  • F. HOFFMANN-LA ROCHE LTD
  • GLAXOSMITHKLINE
  • ABBOTT
  • CSL LTD
目錄
Product Code: 30758

KEY FINDINGS

The global influenza vaccine market is estimated to record a CAGR of 6.43% over the forecast period of 2020-2028. A surge in the cases of influenza is a significant factor fueling the market growth. The other driving factors for the market are the government immunization programs to eradicate ailments from society, along with technological advancements.

MARKET INSIGHTS

Influenza is an acute respiratory illness caused by the influenza virus that affects the respiratory tract. Influenza viruses change continuously. Hence the vaccines have to be changed annually to match with the circulating influenza strains globally. The focus of various immunization programs is on increasing awareness among people towards vaccinations. For example, NAIIS AND CDC across the U.S. have undertaken some of the successful influenza vaccination initiatives. The recommendations made by the CDC are highly reliable and enhance the utilization of vaccines.

The high cost of vaccine development is one of the challenges faced by the market. The development of vaccines comprises of various phases, and the overall time period required from the development to the launch of the vaccine, may take 15-20 years. The overall development requires high monetary investments, which is estimated to be $200 million and $500 million per vaccine. The intensity of competition is high in the market as the market is dominated by a few established players. The quadrivalent influenza vaccine captured the highest market share in type segment in 2019, and is also estimated to be the fastest-growing influenza vaccine type.

REGIONAL INSIGHTS

The global influenza vaccine market is analyzed on the basis of the markets situated in North America, Europe, Asia Pacific, and the Rest of the world. The North American region dominates in terms of revenue, which is attributed to the rising incidences of influenza.

COMPETITIVE INSIGHTS

The market is dominated by well-established players such as Pfizer, Inc, Merck, Sanofi, Novartis AG, F. Hoffmann-La Roch Ltd, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES `
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. PARENT MARKET ANALYSIS: VACCINE MARKET
  • 3.2. MARKET DEFINITION
  • 3.3. KEY DRIVERS
    • 3.3.1. GOVERNMENT IMMUNIZATION PROGRAMS TO ERADICATE AILMENTS FROM THE SOCIETY
    • 3.3.2. RISE IN THE CASES OF INFLUENZA
    • 3.3.3. TECHNOLOGY ADVANCEMENT
  • 3.4. KEY RESTRAINTS
    • 3.4.1. HIGH COST OF DEVELOPMENT
    • 3.4.2. LENGTHY PROCESS OF DEVELOPMENT

4. KEY ANALYTICS

  • 4.1. KEY INVESTMENT INSIGHTS
  • 4.2. PORTER'S FIVE FORCE ANALYSIS
    • 4.2.1. BUYER POWER
    • 4.2.2. SUPPLIER POWER
    • 4.2.3. SUBSTITUTION
    • 4.2.4. NEW ENTRANTS
    • 4.2.5. INDUSTRY RIVALRY
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE

5. MARKET BY TYPE

  • 5.1. QUADRIVALENT VACCINE
  • 5.2. TRIVALENT VACCINE

6. MARKET BY TECHNOLOGY

  • 6.1. EGG-BASED TECHNOLOGY
  • 6.2. CELL-BASED TECHNOLOGY

7. MARKET BY AGE GROUP

  • 7.1. PEDIATRIC AGE GROUP
  • 7.2. ADULT AGE GROUP

8. MARKET BY DELIVERY MODE

  • 8.1. INJECTION
  • 8.2. NASAL SPRAY

9. GEOGRAPHICAL ANALYSIS

  • 9.1. NORTH AMERICA
    • 9.1.1. UNITED STATES
    • 9.1.2. CANADA
  • 9.2. EUROPE
    • 9.2.1. UNITED KINGDOM
    • 9.2.2. GERMANY
    • 9.2.3. FRANCE
    • 9.2.4. ITALY
    • 9.2.5. RUSSIA
    • 9.2.6. BELGIUM
    • 9.2.7. POLAND
    • 9.2.8. REST OF EUROPE
  • 9.3. ASIA PACIFIC
    • 9.3.1. CHINA
    • 9.3.2. JAPAN
    • 9.3.3. INDIA
    • 9.3.4. SOUTH KOREA
    • 9.3.5. AUSTRALIA & NEW ZEALAND
    • 9.3.6. THAILAND
    • 9.3.7. INDONESIA
    • 9.3.8. VIETNAM
    • 9.3.9. REST OF ASIA PACIFIC
  • 9.4. REST OF WORLD
    • 9.4.1. LATIN AMERICA
    • 9.4.2. MIDDLE EAST & AFRICA

10. COMPANY PROFILES

  • 10.1. MERCK
  • 10.2. NOVARTIS AG
  • 10.3. PFIZER, INC
  • 10.4. SANOFI
  • 10.5. BIODIEM
  • 10.6. EMERGENT BIOSOLUTIONS
  • 10.7. F. HOFFMANN-LA ROCHE LTD
  • 10.8. GLAXOSMITHKLINE
  • 10.9. ABBOTT
  • 10.10. CSL LTD

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - INFLUENZA VACCINE
  • TABLE 2: GLOBAL INFLUENZA VACCINE MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: GLOBAL INFLUENZA VACCINE MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL QUADRIVALENT VACCINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL QUADRIVALENT VACCINE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL TRIVALENT VACCINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL TRIVALENT VACCINE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL INFLUENZA VACCINE MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL INFLUENZA VACCINE MARKET, BY TECHNOLOGY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL EGG-BASED TECHNOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: GLOBAL EGG-BASED TECHNOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL CELL-BASED TECHNOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: GLOBAL CELL-BASED TECHNOLOGY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL INFLUENZA VACCINE MARKET, BY AGE GROUP, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: GLOBAL INFLUENZA VACCINE MARKET, BY AGE GROUP, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL PEDIATRIC AGE GROUP MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: GLOBAL PEDIATRIC AGE GROUP MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL ADULT AGE GROUP MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 19: GLOBAL ADULT AGE GROUP MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL INFLUENZA VACCINE MARKET, BY DELIVERY MODE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 21: GLOBAL INFLUENZA VACCINE MARKET, BY DELIVERY MODE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL INJECTION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 23: GLOBAL INJECTION MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL NASAL SPRAY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 25: GLOBAL NASAL SPRAY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 26: GLOBAL INFLUENZA VACCINE MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 27: GLOBAL INFLUENZA VACCINE MARKET, BY GEOGRAPHY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 28: NORTH AMERICA INFLUENZA VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 29: NORTH AMERICA INFLUENZA VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 30: EUROPE INFLUENZA VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 31: EUROPE INFLUENZA VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 32: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 33: ASIA PACIFIC INFLUENZA VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 34: REST OF WORLD INFLUENZA VACCINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 35: REST OF WORLD INFLUENZA VACCINE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: KEY INVESTMENT INSIGHTS
  • FIGURE 2: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 3: OPPORTUNITY MATRIX
  • FIGURE 4: VENDOR LANDSCAPE
  • FIGURE 5: GLOBAL INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2019
  • FIGURE 6: GLOBAL INFLUENZA VACCINE MARKET, BY QUADRIVALENT VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL INFLUENZA VACCINE MARKET, BY TRIVALENT VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2019
  • FIGURE 9: GLOBAL INFLUENZA VACCINE MARKET, BY EGG-BASED TECHNOLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL INFLUENZA VACCINE MARKET, BY CELL-BASED TECHNOLOGY, 2020-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY AGE GROUP, IN 2019
  • FIGURE 12: GLOBAL INFLUENZA VACCINE MARKET, BY PEDIATRIC AGE GROUP, 2020-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL INFLUENZA VACCINE MARKET, BY ADULT AGE GROUP, 2020-2028 (IN $ MILLION)
  • FIGURE 14: GLOBAL INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY DELIVERY MODE, IN 2019
  • FIGURE 15: GLOBAL INFLUENZA VACCINE MARKET, BY INJECTION, 2020-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL INFLUENZA VACCINE MARKET, BY NASAL SPRAY, 2020-2028 (IN $ MILLION)
  • FIGURE 17: NORTH AMERICA INFLUENZA VACCINE MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 18: UNITED STATES INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 19: CANADA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 20: EUROPE INFLUENZA VACCINE MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 21: UNITED KINGDOM INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 22: GERMANY INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 23: FRANCE INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 24: ITALY INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 25: RUSSIA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 26: BELGIUM INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 27: POLAND INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 28: REST OF EUROPE INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 29: ASIA PACIFIC INFLUENZA VACCINE MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 30: CHINA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 31: JAPAN INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 32: INDIA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 33: SOUTH KOREA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 34: AUSTRALIA & NEW ZEALAND INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 35: THAILAND INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 36: INDONESIA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 37: VIETNAM INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 38: REST OF ASIA PACIFIC INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 39: REST OF WORLD INFLUENZA VACCINE MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 40: LATIN AMERICA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 41: MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)